AstraZeneca Announces £37bn US Investment in Response to Tariff Concerns

AstraZeneca has just revealed a bold plan to invest $50 billion (£37 billion) in the United States over the next five years, stretching through 2030. This massive commitment, announced on July 21, 2025, aims to strengthen its position in its biggest market while tackling growing concerns about tariffs on drug imports. For anyone watching the stock market, this move signals confidence and ambition from a company aiming to hit $80 billion in yearly revenue by the decade’s end.